Increased efficacy of dual proinflammatory cytokine blockade on acute GVHD while maintaining GVT effects
© 2021 by The American Society of Hematology..
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains a potential curative option for treating a variety of hematologic diseases, but acute and chronic graft-versus-host disease (GVHD) remain major barriers limiting efficacy. Acute gut GVHD occurs with marked increases in proinflammatory cytokines (including TNF and IL-6), which we recently demonstrated was exacerbated in obesity resulting in severe gastrointestinal pathology. Given the pleiotropic and overlapping effects of these 2 cytokines, we assessed the impact of dual TNF and IL-6R blockade on GVHD as well as graft-versus tumor (GVT) effects in different mouse GVHD models. Early administration of combined blockade resulted in greater protection and survival from acute gut GVHD compared with single blockade regimens and even development of later chronic skin GVHD. Importantly, double cytokine blockade preserved GVT effects reinforcing that GVT and GVHD can be delineated and may result in greater efficacy in allo-HSCT.
| Errataetall: |
CommentIn: Blood. 2021 Dec 16;138(24):2453-2454. - PMID 34914834 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:138 |
|---|---|
| Enthalten in: |
Blood - 138(2021), 24 vom: 16. Dez., Seite 2583-2588 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Khuat, Lam T [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anti-Inflammatory Agents |
|---|
| Anmerkungen: |
Date Completed 03.01.2022 Date Revised 26.02.2024 published: Print CommentIn: Blood. 2021 Dec 16;138(24):2453-2454. - PMID 34914834 Citation Status MEDLINE |
|---|
| doi: |
10.1182/blood.2021011216 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM329682628 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM329682628 | ||
| 003 | DE-627 | ||
| 005 | 20240229153629.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1182/blood.2021011216 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1306.xml |
| 035 | |a (DE-627)NLM329682628 | ||
| 035 | |a (NLM)34424962 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Khuat, Lam T |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Increased efficacy of dual proinflammatory cytokine blockade on acute GVHD while maintaining GVT effects |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 03.01.2022 | ||
| 500 | |a Date Revised 26.02.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a CommentIn: Blood. 2021 Dec 16;138(24):2453-2454. - PMID 34914834 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2021 by The American Society of Hematology. | ||
| 520 | |a Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains a potential curative option for treating a variety of hematologic diseases, but acute and chronic graft-versus-host disease (GVHD) remain major barriers limiting efficacy. Acute gut GVHD occurs with marked increases in proinflammatory cytokines (including TNF and IL-6), which we recently demonstrated was exacerbated in obesity resulting in severe gastrointestinal pathology. Given the pleiotropic and overlapping effects of these 2 cytokines, we assessed the impact of dual TNF and IL-6R blockade on GVHD as well as graft-versus tumor (GVT) effects in different mouse GVHD models. Early administration of combined blockade resulted in greater protection and survival from acute gut GVHD compared with single blockade regimens and even development of later chronic skin GVHD. Importantly, double cytokine blockade preserved GVT effects reinforcing that GVT and GVHD can be delineated and may result in greater efficacy in allo-HSCT | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 7 | |a Anti-Inflammatory Agents |2 NLM | |
| 650 | 7 | |a Antibodies, Monoclonal |2 NLM | |
| 650 | 7 | |a Receptors, Interleukin-6 |2 NLM | |
| 650 | 7 | |a Tumor Necrosis Factor Inhibitors |2 NLM | |
| 650 | 7 | |a Etanercept |2 NLM | |
| 650 | 7 | |a OP401G7OJC |2 NLM | |
| 700 | 1 | |a Vick, Logan V |e verfasserin |4 aut | |
| 700 | 1 | |a Dunai, Cordelia |e verfasserin |4 aut | |
| 700 | 1 | |a Collins, Craig P |e verfasserin |4 aut | |
| 700 | 1 | |a More, Shyam K |e verfasserin |4 aut | |
| 700 | 1 | |a Le, Catherine T |e verfasserin |4 aut | |
| 700 | 1 | |a Pai, Chien-Chun Steven |e verfasserin |4 aut | |
| 700 | 1 | |a Stoffel, Kevin M |e verfasserin |4 aut | |
| 700 | 1 | |a Maverakis, Emanual |e verfasserin |4 aut | |
| 700 | 1 | |a Canter, Robert J |e verfasserin |4 aut | |
| 700 | 1 | |a Monjazeb, Arta M |e verfasserin |4 aut | |
| 700 | 1 | |a Longo, Dan L |e verfasserin |4 aut | |
| 700 | 1 | |a Abedi, Mehrdad |e verfasserin |4 aut | |
| 700 | 1 | |a Choi, Eunju |e verfasserin |4 aut | |
| 700 | 1 | |a Blazar, Bruce R |e verfasserin |4 aut | |
| 700 | 1 | |a Dave, Maneesh |e verfasserin |4 aut | |
| 700 | 1 | |a Murphy, William J |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Blood |d 1946 |g 138(2021), 24 vom: 16. Dez., Seite 2583-2588 |w (DE-627)NLM000014761 |x 1528-0020 |7 nnns |
| 773 | 1 | 8 | |g volume:138 |g year:2021 |g number:24 |g day:16 |g month:12 |g pages:2583-2588 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1182/blood.2021011216 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 138 |j 2021 |e 24 |b 16 |c 12 |h 2583-2588 | ||